Welcome to our dedicated page for Iveric Bio news (Ticker: ISEE), a resource for investors and traders seeking the latest updates and insights on Iveric Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Iveric Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Iveric Bio's position in the market.
IVERIC bio (Nasdaq: ISEE) granted a non-statutory stock option for 14,000 shares to a newly hired employee on October 1, 2020, under its 2019 Inducement Stock Incentive Plan. The stock option's exercise price is set at $5.98, equivalent to the closing stock price on the grant date. It has a ten-year term and vests over four years, with 25% vesting on October 1, 2021, followed by monthly vesting. This grant aimed to incentivize the employee's acceptance of the position, adhering to Nasdaq Listing Rule 5635(c)(4).
IVERIC bio, Inc. (Nasdaq: ISEE) reported positive 18-month results from its Phase 3 trial (OPH2003) for Zimura® (avacincaptad pegol), a complement C5 inhibitor for geographic atrophy due to age-related macular degeneration (AMD). The data indicates a 28.11% and 29.97% reduction in GA growth for the Zimura 2 mg and 4 mg groups, respectively, compared to the sham control. The treatment showed a favorable safety profile, with no significant adverse events. The company plans to initiate its second pivotal trial (ISEE2008) soon, enhancing its position in a market lacking approved therapies.